Artiva Biotherapeutics, Inc. financial data

Symbol
ARTV on Nasdaq
Location
5505 Morehouse Drive, San Diego, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.37K %
Debt-to-equity 13.5 %
Return On Equity -50 % -167%
Return On Assets -44.1 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 24.5M shares +1.05%
Entity Public Float 0 USD
Common Stock, Value, Issued 3K USD 0%
Weighted Average Number of Shares Outstanding, Basic 24.5M shares +29.6%
Weighted Average Number of Shares Outstanding, Diluted 24.5M shares +29.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 65.9M USD +30.4%
General and Administrative Expense 20.3M USD +9.42%
Operating Income (Loss) -86.1M USD -24.9%
Nonoperating Income (Expense) 6.96M USD +58.6%
Net Income (Loss) Attributable to Parent -79.2M USD -29.2%
Earnings Per Share, Basic 31 USD/shares +4.35%
Earnings Per Share, Diluted 31 USD/shares +4.35%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.5M USD -54.4%
Cash, Cash Equivalents, and Short-term Investments 123M USD -38.4%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Assets, Current 130M USD -14%
Property, Plant and Equipment, Net 6.98M USD +1.81%
Operating Lease, Right-of-Use Asset 11.3M USD -21.7%
Other Assets, Noncurrent 418K USD +40.3%
Assets 149M USD -34%
Accounts Payable, Current 848K USD -30.2%
Employee-related Liabilities, Current 5.64M USD +17.4%
Accrued Liabilities, Current 7.03M USD -15.8%
Liabilities, Current 11.1M USD -16.3%
Operating Lease, Liability, Noncurrent 8.52M USD -23.7%
Other Liabilities, Noncurrent 73K USD 0%
Liabilities 19.6M USD -20.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 87K USD -74.3%
Retained Earnings (Accumulated Deficit) -310M USD -34.3%
Stockholders' Equity Attributable to Parent 129M USD -35.7%
Liabilities and Equity 149M USD -34%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -19.8M USD -31.5%
Net Cash Provided by (Used in) Financing Activities 239K USD
Net Cash Provided by (Used in) Investing Activities 9.97M USD +1.93%
Common Stock, Shares Authorized 700M shares
Common Stock, Shares, Issued 424K shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.63M USD -81.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 26M USD -53.7%
Deferred Tax Assets, Valuation Allowance 63.1M USD +43.1%
Deferred Tax Assets, Gross 68.2M USD +35.3%
Operating Lease, Liability 11.6M USD -21.4%
Depreciation 2.4M USD 0%
Payments to Acquire Property, Plant, and Equipment 511K USD +2739%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -79.4M USD -24.3%
Lessee, Operating Lease, Liability, to be Paid 13.5M USD -24.7%
Property, Plant and Equipment, Gross 14.8M USD +21.4%
Operating Lease, Liability, Current 3.1M USD -14.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.5M USD +2.31%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.42M USD -14.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.84M USD -40.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.6M USD +2.36%
Deferred Tax Assets, Operating Loss Carryforwards 29.7M USD +45.4%
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 5M USD +24.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.28M USD
Depreciation, Depletion and Amortization 628K USD +6.99%
Deferred Tax Assets, Net of Valuation Allowance 5.07M USD -19.1%
Share-based Payment Arrangement, Expense 7.42M USD -14.5%